Precipio, Inc. (NASDAQ:PRPO) Sees Large Decrease in Short Interest

Precipio, Inc. (NASDAQ:PRPO) was the target of a significant decline in short interest during the month of December. As of December 15th, there was short interest totaling 4,124 shares, a decline of 44.2% from the November 30th total of 7,388 shares. Approximately 0.3% of the company’s shares are sold short. Based on an average daily volume of 9,360 shares, the short-interest ratio is currently 0.4 days. Based on an average daily volume of 9,360 shares, the short-interest ratio is currently 0.4 days. Approximately 0.3% of the company’s shares are sold short.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in PRPO. AMH Equity Ltd boosted its stake in shares of Precipio by 370.1% during the 3rd quarter. AMH Equity Ltd now owns 131,100 shares of the biotechnology company’s stock valued at $2,332,000 after purchasing an additional 103,210 shares in the last quarter. Topline Capital Management LLC purchased a new stake in Precipio in the third quarter worth about $1,158,000. Evernest Financial Advisors LLC bought a new stake in Precipio during the 3rd quarter valued at approximately $374,000. Finally, Susquehanna International Group LLP bought a new position in shares of Precipio in the 3rd quarter worth approximately $194,000. 10.45% of the stock is owned by hedge funds and other institutional investors.

Precipio Stock Down 1.6%

Shares of NASDAQ:PRPO opened at $23.50 on Friday. The stock’s 50-day moving average is $22.53 and its 200 day moving average is $17.83. The company has a market cap of $41.13 million, a PE ratio of -28.66 and a beta of 1.09. The company has a debt-to-equity ratio of 0.06, a current ratio of 1.27 and a quick ratio of 1.10. Precipio has a 1 year low of $3.90 and a 1 year high of $28.50.

Precipio (NASDAQ:PRPO) last released its quarterly earnings data on Friday, November 14th. The biotechnology company reported ($0.05) earnings per share for the quarter. Precipio had a negative return on equity of 10.07% and a negative net margin of 5.50%.The business had revenue of $6.77 million during the quarter.

Wall Street Analysts Forecast Growth

A number of research analysts have recently issued reports on the company. Wall Street Zen cut Precipio from a “buy” rating to a “hold” rating in a research note on Saturday, November 15th. Weiss Ratings reissued a “sell (d-)” rating on shares of Precipio in a research note on Wednesday, October 8th. One analyst has rated the stock with a Sell rating, According to MarketBeat, the stock presently has an average rating of “Sell”.

Precipio Company Profile

Precipio, Inc is a clinical-stage diagnostics and medical technology company focused on advancing the detection and management of hematologic diseases. The firm develops precision diagnostic solutions that integrate digital morphology, immunophenotyping, and molecular testing to improve the diagnosis of leukemia and related blood disorders. Precipio’s approach is designed to enhance the accuracy and speed of laboratory workflows, helping physicians tailor treatment strategies more effectively.

The company’s core offerings include an automated digital imaging and analysis platform that captures and classifies blood and bone marrow cell images at high throughput.